Ibuprofen Dependence: A Case Report

F. Etcheverrigaray; M. Grall-Bronnec; M.-C. Blanchet; P. Jolliet; C. Victorri-Vigneau

doi:10.1055/s-0034-1371868

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2014; 47(03): 115-117
DOI: 10.1055/s-0034-1371868

Letter

Ibuprofen Dependence: A Case Report

F. Etcheverrigaray^*

¹Center for Evaluation and Information on Pharmacodependence, Clinical Pharmacology Department, University Hospital, Nantes, France

,

M. Grall-Bronnec^*

²Addictology and Psychiatry Department, University Hospital, Nantes, France

³EA 4275, Biostatistics, Pharmacoepidemiology and Subjective Measures in Health Sciences, Nantes University, Nantes, France

,

M.-C. Blanchet

²Addictology and Psychiatry Department, University Hospital, Nantes, France

,

P. Jolliet

¹Center for Evaluation and Information on Pharmacodependence, Clinical Pharmacology Department, University Hospital, Nantes, France

³EA 4275, Biostatistics, Pharmacoepidemiology and Subjective Measures in Health Sciences, Nantes University, Nantes, France

,

C. Victorri-Vigneau

¹Center for Evaluation and Information on Pharmacodependence, Clinical Pharmacology Department, University Hospital, Nantes, France

³EA 4275, Biostatistics, Pharmacoepidemiology and Subjective Measures in Health Sciences, Nantes University, Nantes, France

› Author Affiliations

Abstract

Ibuprofen is currently widely prescribed and has not been reported to produce dependence. We report the case of a 17-year old patient who presented many positive psychics symptoms related to a pharmacological dependence. During the treatment, she adjusted herself posology as she developed withdrawal symptoms. Pharmacological evidences (effect on COX-1 and COX-2, FAAH and PPARs) allow us to formulate hypotheses explaining this effect.

Key words

ibuprofen - dependence - cannabinoid receptor modulators - peroxisome proliferator-activated

Full Text

References

References
1 American Psychiatric Association . Diagnostic and statistical manual of mental disorders DSM-IV-TR. Washington, DC: American Psychiatric Publishing; 2000
2 American Psychiatric Association . Diagnostic and statistical manual of mental disorders DSM-5. Washington, DC: American Psychiatric Publishing; 2013
3 Zwart J-A, Dyb G, Hagen K et al. Analgesic overuse among subjects with headache, neck, and low-back pain. Neurology 2004; 62: 1540-1544
4 Abrams BM. Medication overuse headaches. Med Clin North Am 2013; 97: 337-352
5 Elkind AH. Drug abuse and headache. Med Clin North Am 1991; 75: 717-732
6 Beaulieu P, Lambert C. Précis de pharmacologie. Du fondamental à la clinique. Les Presses de l’Université de Montréal 2010
7 Ito S, Okuda-Ashitaka E, Minami T. Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci Res 2001; 41: 299-332
8 Wu KK-Y. Biochemical pharmacology of nonsteroidal anti-inflammatory drugs. Biochem Pharmacol 1998; 55: 543-547
9 Nechifor M, Chelãrescu D, Teslariu E et al. Effects of PGF2alpha analogues in experimental morphine-induced pharmacodependence. Adv Exp Med Biol 2003; 525: 121-124
10 Nakagawa T, Minami M, Katsumata S et al. Suppression of naloxone-precipitated withdrawal jumps in morphine-dependent mice by stimulation of prostaglandin EP3 receptor. Br J Pharmacol 1995; 116: 2661-2666
11 Dajani EZ, Shahwan TG, Dajani NE. Prostaglandins and brain-gut axis. J Physiol Pharmacol Off J Pol Physiol Soc 2003; 54 (Suppl. 04) 155-164
12 Paunescu H, Coman OA, Coman L et al. Cannabinoid system and cyclooxygenases inhibitors. J Med Life 2011; 4: 11
13 De Petrocellis L, Melck D, Ueda N et al. Brain and peripheral anandamide amidohydrolase and its inhibition by synthetic arachidonate analogues. Adv Exp Med Biol 1997; 433: 259-263
14 Pertwee RG. Pharmacological actions of cannabinoids. Handb Exp Pharmacol 2005; 1-51
15 Solinas M, Tanda G, Justinova Z et al. The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther 2007; 321: 370-380
16 Ramesh D, Gamage TF, Vanuytsel T et al. Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2013; 38: 1039-1049
17 Solinas M, Justinova Z, Goldberg SR et al. Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem 2006; 98: 408-419
18 Gamaleddin I, Wertheim C, Zhu AZX et al. Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking. Addict Biol 2012; 17: 47-61
19 Romero TRL, Resende LC, Guzzo LS et al. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system. Anesth Analg 2013; 116: 463-472
20 Moreira FA, Lutz B. The endocannabinoid system: emotion, learning and addiction. Addict Biol 2008; 13: 196-212
21 Sim-Selley LJ. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 2003; 15: 91-119
22 Lenhard JM. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272: 3406-3410
23 Jaradat MS, Wongsud B, Phornchirasilp S et al. Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol 2001; 62: 1587-1595
24 Pontieri FE, Tanda G, Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the “shell” as compared with the “core” of the rat nucleus accumbens. Proc Natl Acad Sci USA 1995; 92: 12304-12308
25 Schlicht I. Enhancement of voluntary alcohol consumption in rats by clofibrate feeding. Alcohol Fayettev N 1987; 4: 199-206
26 Barson JR, Karatayev O, Chang G-Q et al. Positive relationship between dietary fat, ethanol intake, triglycerides, and hypothalamic peptides: counteraction by lipid-lowering drugs. Alcohol Fayettev N 2009; 43: 433-441
27 Fernandez-Espejo E, Ramiro-Fuentes S, Rodriguez de Fonseca F. The absence of a functional peroxisome proliferator-activated receptor-alpha gene in mice enhances motor sensitizing effects of morphine, but not cocaine. Neuroscience 2009; 164: 667-675
28 Panlilio LV, Justinova Z, Mascia P et al. Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2012; 37: 1838-1847
29 Stopponi S, Somaini L, Cippitelli A et al. Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Biol Psychiatry 2011; 6: 642-649
30 Maeda T, Kiguchi N, Fukazawa Y et al. Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2007; 32: 1133-1140
31 Mascia P, Pistis M, Justinova Z et al. Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry 2011; 69: 633-641
32 Sarruf DA, Yu F, Nguyen HT et al. Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology 2009; 150: 707-712